Table 2. Resistance proportions by year of isolation for the 253 non-Global Antimicrobial Resistance Surveillance System pathogens isolated from children at Angkor Hospital for Children, Siem Reap, Cambodia, 2007–2016*.
| Pathogen, resistance type | No. isolates resistant/no. tested (%) | Year of isolation |
||||
|---|---|---|---|---|---|---|
| 2007–2008 | 2009–2010 | 2011–2012 | 2013–2014 | 2015–2016 | ||
| Burkholderia pseudomallei | 66 | 6 | 10 | 13 | 22 | 15 |
| CAZ | 0/66 | 0/6 | 0/10 | 0/13 | 0/22 | 0/15 |
| TMP/SXT |
0/61 |
0/2 |
0/10 |
0/12 |
0/22 |
0/15 |
| Haemophilus influenzae | 57 | 15 | 15 | 9 | 12 | 6 |
| AMP | 30/56 (53.6) | 5/14 (35.7) | 10/15 (66.7) | 7/9 (77.8) | 8/12 (66.7) | 0/6 |
| CRO | 3/57 (5.3) | 1/15 (6.7) | 1/15 (6.7) | 0/9 | 1/12 (8.3) | 0/6 |
| Multidrug |
13/35 (37.1) |
0/0 |
5/10 (50.0) |
5/7 (71.4) |
3/12 (25.0) |
0/6 |
| Enterobacter cloacae | 42 | 2 | 6 | 8 | 17 | 9 |
| AMP–GEN | 19/42 (45.2) | 1/2 (50.0) | 5/6 (83.3) | 5/8 (62.5) | 6/17 (35.3) | 2/9 (22.2) |
| 3GC | 34/42 (81.0) | 1/2 (50.0) | 5/6 (83.3) | 7/8 (87.5) | 14/17 (82.4) | 7/9 (77.8) |
| Carbapenem | 3/41 (7.3) | 0/1 | 0/6 | 0/8 | 2/17 (11.8) | 1/9 (11.1) |
| Multidrug |
18/37 (48.6) |
1/1 (100) |
2/2 (100) |
5/8 (62.5) |
7/17 (41.2) |
3/9 (33.3) |
| Group A Streptococcus | 38 | 2 | 6 | 6 | 13 | 11 |
| MAC/LIN |
6/37 (16.2) |
0/2 |
1/5 (20.0) |
0/6 |
2/13 (15.4) |
3/11 (27.3) |
| Pseudomonas aeruginosa | 37 | 7 | 6 | 7 | 9 | 8 |
| CAZ | 4/34 (11.8) | 0/4 | 1/6 (16.7) | 1/7 (14.3) | 2/9 (22.2) | 0/8 |
| Carbapenem | 2/30 (6.7) | 0/1 | 0/5 | 1/7 (14.3) | 0/9 | 1/8 (12.5) |
| Multidrug |
0/29 |
0/0 |
0/5 |
0/7 |
0/9 |
0/8 |
| Neisseria meningitidis | 13 | 6 | 3 | 0 | 2 | 2 |
| CRO | 1/13 (7.7) | 0/6 | 1/3 (33.3) | 0/2 | 0/2 | |
*Resistance proportions have been reported as number of resistant isolates out of number of isolates tested. Blank cell indicates that no organisms were tested during that period and, thus, the proportion of resistant organisms is unknown. 3GC, third-generation cephalosporin; AMP–GEN, resistance to both ampicillin and gentamicin; CAZ, ceftazidime; CRO, ceftriaxone; MAC/LIN, resistance to macrolides and/or lincosamides; TMP/SXT, trimethoprim/sulfamethoxazole.